MedTrace Logo

RAD001 for Patients With Radioiodine Refractory Thyroid Cancer

NCT00936858 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2021-10-22

Study results available
· View outcomes & findings →

Summary

Since thyroid cancer becomes refractory to radioactive iodine, treatment options are very limited. Tyrosine kinase inhibitors such as sorafenib have recently shown promise. This trial seeks to expand treatment options for this disease with a new, oral drug called RAD001. It is an inhibitor of the mTOR pathway and has shown activity in neuroendocrine cancers of the gastrointestinal tract and has been approved for the treatment of metastatic renal cell cancer.

Conditions

Interventions

DRUG

RAD001

Sponsors & Collaborators

  • Massachusetts General Hospital

    collaborator OTHER

  • M.D. Anderson Cancer Center

    collaborator OTHER

  • MOUNT SINAI HOSPITAL

    collaborator OTHER

  • Novartis

    collaborator INDUSTRY

  • Dana-Farber Cancer Institute

    lead OTHER

Principal Investigators

  • Glenn Hanna, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2020-02-27
Completion
2020-02-27

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00936858 on ClinicalTrials.gov